Fennec Posts 50% FY Sales Growth, 75% Q4 Increase and $42M Raise
Fennec reported FY2025 net product sales of $44.6M, up 50% YoY, and Q4 sales of $13.8M, up 75%, supported by a $42M oversubscribed equity offering. Positive topline results from a Phase 2/3 Japanese trial and institution-led studies support PEDMARK’s reduction of cisplatin-induced hearing loss in pediatric and AYA cancer patients.
1. Record Sales Growth
Fennec delivered net product sales of $13.8 million in Q4 2025, a 75% increase over Q4 2024, driving full-year sales to $44.6 million, up 50% from 2024, reflecting strong adoption across key oncology accounts.
2. Oversubscribed Equity Offering
The company completed an oversubscribed $42 million equity offering in Q4, bolstering its balance sheet and enabling full debt redemption to support future growth and operational flexibility.
3. Clinical Progress
Positive topline data from the Phase 2/3 STS-J01 trial in Japan demonstrated PEDMARK’s efficacy in reducing cisplatin-induced hearing loss with no impact on antitumor activity, complemented by new institution-led studies at City of Hope and Tampa General.
4. Commercial Expansion
Fennec expanded its field team during Q4 to increase penetration in community oncology centers and the adolescent and young adult (AYA) segment while pursuing Japanese registration and potential licensing partnerships for PEDMARK.